SCHEMBL3797922

SCHEMBL3797922

CCOC(=O)CCc1cc(F)c(F)c(C2CO2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.44
CYP4A11 Q02928 2/20 0.44
HRH3 Q9Y5N1 1/20 0.37
CYP4Z1 Q86W10 1/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.35
TNF P01375 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
P2RY12 Q9H244 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3797924 1.00 CYP4F2 (0.44) CYP4F2CYP4A11HRH3CYP4Z1ALDH1A1
SCHEMBL3799726 0.79 CYP4F2 (0.50) CYP4F2CYP4A11CYP4Z1ALDH1A1GAA
SCHEMBL3795745 0.78 CYP4F2 (0.50) CYP4F2CYP4A11HRH3CYP4Z1ALDH1A1
SCHEMBL2302006 0.77 CYP4F2 (0.54) CYP4F2CYP4A11CYP4Z1ALDH1A1GAA
SCHEMBL3803591 0.75 F10 (0.32) ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3803593 0.75 F10 (0.32) ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3800196 0.75 CYP4F2 (0.46) CYP4F2CYP4A11CYP4Z1ALDH1A1GAA
SCHEMBL17185943 0.75 CYP4F2 (0.55) CYP4F2CYP4A11HRH3CYP4Z1ALDH1A1
SCHEMBL7857817 0.74 CYP4F2 (0.57) CYP4F2CYP4A11HRH3CYP4Z1KDM4E
SCHEMBL17197084 0.73 CYP4F2 (0.50) CYP4F2CYP4A11HRH3CYP4Z1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902394-B2 Calcilytic compounds GLAXOSMITHKLINE LLC (US) 2011-03-08 US disclosed
US-20100029782-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION (US) 2010-02-04 US disclosed
EP-2120898-A1 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2009-11-25 EP disclosed
WO-2008077009-A1 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029782-A1 Calcilytic Compounds CALCR, CALCA, CALCB CYP4F2 394/4885CYP4A11 282/4885HRH3 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.